Related Experiment Videos
Two neutralizing human anti-RSV antibodies: cloning, expression, and characterization.
Molecular Medicine (Cambridge, Mass.)
|March 11, 1999
Summary
Researchers developed a new method to create high-affinity human antibodies for respiratory syncytial virus (RSV) immunotherapy. This technique uses SCID mice and CHO cells to generate neutralizing antibodies, offering a promising approach for treating RSV infections.
Area of Science:
- Immunology
- Virology
- Biotechnology
Background:
- Respiratory syncytial virus (RSV) poses a significant health risk to newborns and the elderly.
- Fully human monoclonal antibodies neutralizing RSV are crucial for immunotherapy.
- Generating human antibodies in vitro has been challenging due to difficulties in activating B cells.
Purpose of the Study:
- To develop a method for generating high-affinity human monoclonal antibodies against RSV.
- To investigate the potential of a novel B cell immortalization technique for antibody production.
Main Methods:
- Human spleen cells from RSV-exposed individuals were used to repopulate SCID mice.
- SCID mice were immunized with RSV fusion (F)-protein, leading to B cell tumor formation.
- Tumors were cultured with T cells, yielding antibodies RF-1 and RF-2; VH and VL genes were cloned.
Main Results:
- Antibodies RF-1 and RF-2 demonstrated high affinity for RSV F-protein (0.1 nM and 0.07 nM, respectively).
- Both antibodies effectively neutralized multiple RSV subtypes (A and B).
- VH genes belonged to the VH2 family, and Vk genes to the VK III family.
Conclusions:
- A novel technique involving SCID mice and CHO cells enables the development of high-affinity human antibodies.
- This method offers a viable strategy for producing therapeutic antibodies for viral diseases like RSV.
- The generated antibodies show promise for the immunotherapy of RSV infections.